RXFP3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL27001790	1.00	18/20
SCHEMBL27001795	1.00	18/20
SCHEMBL27001805	1.00	18/20
SCHEMBL27001806	1.00	18/20
SCHEMBL27001808	1.00	18/20
SCHEMBL27001816	1.00	18/20
SCHEMBL27001821	1.00	18/20
SCHEMBL27001824	1.00	18/20
SCHEMBL27001826	1.00	18/20
SCHEMBL27001830	1.00	18/20
SCHEMBL27001833	1.00	18/20
SCHEMBL27001838	1.00	18/20
SCHEMBL27412596	1.00	18/20
SCHEMBL27001823	0.92	18/20
SCHEMBL27001810	0.91	18/20
SCHEMBL27001831	0.90	18/20
SCHEMBL27001815	0.90	18/20
SCHEMBL27001837	0.88	18/20
SCHEMBL27001788	0.86	18/20
SCHEMBL27001799	0.85	18/20

Clinical trials — most relevant to RXFP3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
A Study Of The Usage Of Statins In A Community Heart Failure Population	PHASE4	COMPLETED
Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation	PHASE4	COMPLETED
Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.	PHASE3	UNKNOWN
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure	PHASE2/PHASE3	COMPLETED
Liraglutide in Adolescents With Type 1 Diabetes	PHASE3	COMPLETED
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET	PHASE2/PHASE3	COMPLETED
DILIPO (DILutIonal HyPOnatremia)	PHASE3	COMPLETED
Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis	PHASE2/PHASE3	RECRUITING
Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure	PHASE2	COMPLETED
Effects of Exenatide on Hypothalamic Obesity	PHASE1/PHASE2	COMPLETED
Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36	PHASE1/PHASE2	COMPLETED
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans	PHASE2	NOT_YET_RECRUITING
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes	PHASE2	RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)	nan	COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)	nan	COMPLETED
Gastroparesis Registry 3	nan	COMPLETED
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention	nan	NOT_YET_RECRUITING
Relaxin Measurement in Different Endometrial Preparation Approaches for Frozen Embryo Transfer	nan	RECRUITING
Effect of Urocortins in Patients With Heart Failure	nan	COMPLETED
Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome	nan	COMPLETED
Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus	nan	NOT_YET_RECRUITING
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	nan	RECRUITING
Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure	nan	UNKNOWN
Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases	nan	COMPLETED
The Effect of Weekly Semaglutide Treatment on Energy Expenditure	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RXFP3 binder may also engage these)

Protein	Name	Similarity
Q8BGE9	—	1.000	Q8BGE9 →
O97661	—	0.978	O97661 →
HCRTR1	Orexin/Hypocretin receptor type 1	0.974	landscape →
Q60613	—	0.974	Q60613 →
Q9EP86	—	0.974	Q9EP86 →
P11617	—	0.973	P11617 →
Q8VIH9	—	0.973	Q8VIH9 →
Q0GBZ5	—	0.973	Q0GBZ5 →
B4XF06	—	0.972	B4XF06 →
P49220	—	0.971	P49220 →
P56718	—	0.971	P56718 →
NPFFR1	Neuropeptide FF receptor 1	0.971	landscape →
P49684	—	0.971	P49684 →
Q7TQN7	—	0.970	Q7TQN7 →
GPR39	G-protein coupled receptor 39	0.969	landscape →
P30935	—	0.969	P30935 →
Q7TQP2	—	0.968	Q7TQP2 →
Q9WV08	—	0.968	Q9WV08 →
P30936	—	0.968	P30936 →
O62809	—	0.967	O62809 →
P31392	—	0.967	P31392 →
C8YUV0	—	0.967	C8YUV0 →
Q6TLI7	—	0.967	Q6TLI7 →
FFAR4	Free fatty acid receptor 4	0.967	landscape →
P43142	—	0.967	P43142 →
P58307	—	0.966	P58307 →
P58308	—	0.966	P58308 →
P30543	—	0.966	P30543 →
ADORA2A	Adenosine receptor A2a	0.965	landscape →
Q5U431	—	0.965	Q5U431 →